Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis

Background & Aims: The safety, tolerability, and efficacy of the non-bile acid farnesoid X receptor agonist tropifexor were evaluated in a phase II, double-blind, placebo-controlled study as potential second-line therapy for patients with primary biliary cholangitis (PBC) with an inadequate...

Full description

Bibliographic Details
Main Authors: Christoph Schramm, Heiner Wedemeyer, Andrew Mason, Gideon M. Hirschfield, Cynthia Levy, Kris V. Kowdley, Piotr Milkiewicz, Ewa Janczewska, Elena Sergeevna Malova, Johanne Sanni, Phillip Koo, Jin Chen, Subhajit Choudhury, Lloyd B. Klickstein, Michael K. Badman, David Jones
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:JHEP Reports
Subjects:
Tropifexor
Farnesoid X receptor
Primary biliary cholangitis
Proof of concept
γ-Glutamyl transferase
Pruritus
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555922001161

Internet

http://www.sciencedirect.com/science/article/pii/S2589555922001161

Similar Items